[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multicenter-observational-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multicenter-observational-study":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100611653",false,"NCT07243379","A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia","Inclusion Criteria:\n\n* Patients with histologically and\u002For cytologically confirmed malignancy.\n* Age ≥18 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and an expected survival of ≥3 months.\n* Meeting the diagnostic criteria for cachexia (based on Fearon's criteria).\n* Body mass index (BMI) ≤30.\n\nExclusion Criteria:\n\n* Presence of any condition affecting gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrolled vomiting; patients receiving tube feeding or parenteral nutrition.\n* Presence of anorexia due to anorexia nervosa, psychiatric disorders, or pain that makes eating difficult.\n* Patients with acquired immunodeficiency syndrome (AIDS).\n* Currently receiving or planning to receive other medications that increase appetite or body weight, such as corticosteroids (except short-term dexamethasone during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.\n* Patients with Cushing's syndrome, adrenal or pituitary insufficiency, or poorly controlled diabetes mellitus.","ALL","18 Years","85 Years",{"count":18,"type":19},495,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.",[25,26],"Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia","Multicenter Observational Study","RECRUITING","2025-11-19",{"date":30,"type":31},"2025-11-21","ACTUAL",{"date":33,"type":31},"2025-09-25",{"date":35,"type":19},"2027-06-30",{"name":37,"class":38},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",""]